Ethical Issues in Clinical Neuroscience Research: A Patient's Perspective

Neurotherapeutics

Volumn 4, Issue 3, 2007, Pages 537-544

  Cohen, Perry D ^a   Herman, Linda ^a   Jedlinski, Sheryl ^a   Willocks, Peggy ^a   Wittekind, Paula ^a  

^a Parkinson Pipeline Project   (United States)

Author keywords

conflict of interest; ethics; Parkinson's disease; patient voice; patient centered care; placebo; sham surgery

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLACEBO;

ARTICLE; CELL TRANSPLANTATION; CLINICAL RESEARCH; CLINICAL TRIAL; CROSSOVER PROCEDURE; ETHICS; FOLLOW UP; GENE THERAPY; HUMAN; MEDICAL CARE; METHODOLOGY; NEUROSCIENCE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT CARE; PATIENT EDUCATION; PATIENT PARTICIPATION; PEER REVIEW; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; HUMAN EXPERIMENTATION; HUMANS; NEUROLOGY; PATIENT-CENTERED CARE;

EID: 34250752739     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2007.04.008     Document Type: Article

References (28)

1. United States Government Accounting Office. New drug development: science, business, regulatory and intellectual property issues cited as hampering drug development efforts. GAO-07-49, a report to congressional requesters (2006). http://www.gao.gov/new.items/d0749.pdf November Available at: http://www.gao.gov/new.items/d0749.pdf. Accessed January 20, 2007.
2. Glass K.C., and Waring D. The physician/investigator's obligation to patients participating in research: the case of placebo controlled trials. J Law Med Ethics 33 (2005) 575-585
3. Getz K.A. Forgotten voices in the transparency debate: online trial registries alone will not succeed at rebuilding public confidence. Appl Clin Trials (2006). http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473 April. Available at: http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=316473. Accessed May 22, 2007.
4. Gullo K. New survey shows public perception of opportunity to participate in clinical trials has decreased slightly from last year. Harris Interactive Healthcare News 5 6 (2005) 1-14. http://www.harrisinteractive.com/news/newsletters/healthnews/HI_HealthCareNews2005Vol5_lss06.pdf Available at: http://www.harrisinteractive.com/news/newsletters/healthnews/HI_HealthCareNews2005Vol5_lss06.pdf.
5. Fox M. Michael's mission [Dateline Interview with Katie Couric] (2006). http://www.michaeljfox.org/newsEvents_michaelInTheNews_article.cfm?ID=28 April 16. Available at: http://www.michaeljfox.org/newsEvents_michaelInTheNews_article.cfm?ID=28. Accessed January 20, 2007.
6. National Consumers League. Survey: Public believes decisions concerning treatment should rest with patients and physicians. NCL News: Releases & Advisories (2006). http://www.nclnet.org/news/2006/chronic_disease_survey_03062006.htm March 6. Available at: http://www.nclnet.org/news/2006/chronic_disease_survey_03062006.htm. Accessed January 20, 2007.
7. Workshop proceedings-Inviting public participation in clinical research: building trust through partnerships. October 26-27, 2004. A workshop sponsored by the National Institutes of Health Director's Council of Public Representatives (COPR); coordinated in partnership with the NIH Public Trust Initiative. Available at: http://copr.nih.gov/reports/October_2004_COPR_WORKSHOP_Proceedings.pdf. Accessed January 20, 2007.
8. Freed C.R., Greene P., Breeze R., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 (2001) 710-719
9. McRae C., Cherin E., Yamazaki T.G., et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 61 (2004) 412-420
10. Kim S.Y., Frank S., Holloway R., Zimmerman C., Wilson R., and Kieburtz K. Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol 62 (2005) 1357-1360
11. U.S. Food and Drug Administration, Department of Health and Human Services. FDA approves implanted brain stimulator to control tremors (1997). http://www.fda.gov/bbs/topics/NEWS/NEW00580.html Released August 4. p97-24. Available at: http://www.fda.gov/bbs/topics/NEWS/NEW00580.html.
12. Polgar S., and Ng J. Ethics, methodology, and the use of placebo controls in surgical trials. Brain Res Bull 67 (2005) 290-297
13. Havemann J. The best medicine may be hope. The Hamilton [Ontario] Spectator (2006). http://www.grassrootsconnection.com/HaveHope.htm November 29; A.7. Available at: http://www.grassrootsconnection.com/HaveHope.htm.
14. Frank S., Kieburtz K., Holloway R., and Kim S.Y.H. Author reply. [to W Landau comment on: What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology 2005;65:1101-1103]. Neurology 66 (2006) 1788-1789
15. Berry D. A guide to drug discovery: Bayesian clinical trials. Nat Rev Drug Discov 5 (2006) 27-36
16. Chebrolu H., Slevin J.T., Gash D.A., et al. MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol 198 (2006) 450-456
17. Hutchinson M., Gurney S., and Newson R. GDNF in Parkinson disease: an object lesson in the tyranny of type II. J Neurosci Methods (2006) (Jul 27) [Epub ahead of print].
18. Lang A.E., Gill S., Patel N.K., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 (2006) 459-466 [Erratum in: Ann Neurol 2006;60:747]
19. Love S., Plaha P., Patel N.K., Hotton G., Brooks D.J., and Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11 (2005) 703-704
20. Patel N.K., Bunnage M., Plaha P., Svendsen C.N., Heywood P., and Gill S.S. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57 (2005) 298-302
21. Penn R.D., Dalvi A., Slevin J., et al. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 5 (2006) 202-203
22. Salvatore M., Ai Y., Fischer B., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202 (2006) 497-505
23. Slevin J.T., Gash D.M., Smith C.D., et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106 (2007) 614-620
24. Fahn S., and Elliott R.A. PDF statement on Amgen's decision to block reinstatement of experimental Parkinson's treatment for trial participants (2005). http://www.pdf.org/Publications/Amgens_Denial_Access.pdf Released February 11. Available at http://www.pdf.org/Publications/Amgens_Denial_Access.pdf. Accessed March 27, 2007.
25. Parkinson's Disease Foundation. Parkinson's Disease Foundation expresses concern at statement on Kentucky court decision supporting Amgen's denial of patient access to GDNF (2005). http://www.pdf.org/Publications/Amgens_Denial_Access.pdf Released July 12. Available at http://www.pdf.org/Publications/Amgens_Denial_Access.pdf. Accessed March 27, 2007.
26. Dresser R. Patient advocates in research: new possibilities, new problems. Wash Univ J Law Policy 11 (2003) 237-248
27. The hard way to a Bill of Rights. [Editorial]. Lancet Neurol 4 (2005) 787
28. Gliklich R. Postapproval needs reassessed: real-world data demands place Phase IV studies in spotlight. Appl Clin Trials (2007). http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=410610 March. Available at http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=410610. Accessed March 27, 2007.